Val curves based on p53 antibody status for the entire population (n = 90)p53 with the individuals was detected in 63 (38/60). There was no important distinction in background amongst the anti-p53 ositive and anti-p53 egative groups.have been 13.3 months and 14.6 months (HR, 0.69; 95 CI, 0.41.17; P = 0.17), respectively (Fig. 1).Correlation among IHC of p53 protein status and clinical outcomes (n = 60)Correlation among anti-p53 antibody status and clinical outcomes (n = 90)Applying RECIST criteria (Table two), the overall response rate (ORR) was 77.7 (42/54) within the anti-p53 egative sufferers and 69.4 (25/36) within the anti-p53 ositive sufferers. The odds ratio was 1.07. Median OS was 36.1 months inside the anti-p53 ositive sufferers and not accessible (NA) in the anti-p53 egative patients [hazard ratio (HR) 0.81, 95 confidence interval (CI) 0.37.77, P = 0.61]. The corresponding values for median PFSORR according to RECIST criteria was 77.7 (14/18) and 76.1 (32/42) inside the p53 protein negative tumors plus the p53 protein constructive tumors, respectively. The odds ratio was 1.09.OS was 33.five months within the p53 protein unfavorable tumors, and NA inside the p53 protein optimistic tumors (HR 0.58, 95 CI 0.21-1.6, P = 0.three). PFS was 13.36 months, and 13.three months (Table 2), respectively (HR 1.0, 95 CI 0.51-1.9, P = 0.99) (Fig. 2). The estimated correlation involving anti-p53 antibody positivity and also the IHCof p53 protein good tumors was 0.32 (95 CI 0.07.53, P = 0.012).Fig. two All round survival and progression-free survival curves in accordance with IHC of p53 protein status (n = 60)Osumi et al. BMC Cancer (2015) 15:Page 5 ofFig. 3 General survival and progression-free survival curves according to p53 antibody status for the KRAS wild-type population (n = 44)Correlation involving anti-p53 antibody status and KRAS genotype (n = 70) (Table two)In the KRAS wild-type (n = 42) sufferers, ORR as outlined by RECIST was 90.9 and 83.eight inside the anti-p53 egative sufferers and anti-p53 ositive individuals, respectively. Median OS was 35.six months in all individuals, 35.six months inside the anti-p53 egative sufferers, and NA inside the antip53 ositive individuals (HR 0.65, 95 CI 0.18.33, P = 0.five). The corresponding values for median PFS were 14.6 months in total, 17.9 months, and 16.7 months, respectively (HR 1.06, 95 CI 0.48.31, P = 0.88) (Fig. 3). Inside the KRAS mutant-type (n = 26) sufferers, ORR in line with RECIST was 69.2 (9/13) and 76.9 (10/13) inside the anti-p53 egative sufferers and anti-p53 ositivepatients, respectively.IL-1 alpha Protein site Median OS was 33.IL-1 beta Protein custom synthesis eight months in all individuals, 13.PMID:23381626 8 months in the anti-p53 egative individuals, and 15.eight months in the anti-p53 ositive individuals (HR 0.52, 95 CI 0.21.28, P = 0.15). The corresponding values for median PFS have been 14.6 months, 34.three months, and 26.6 months, respectively (HR 1.18, 95 CI 0.33.1, P = 0.79) (Fig. 4). The estimated correlation between antip53 antibody positivity and also the KRAS genotype was 0.037 (95 CI 0.20.27, P = 0.746).Univariate and murtivariate analysisIn univariate evaluation, peritoneal metastasis and several metastasis have been also significant predictors of OS. On theFig. four All round survival and progression-free survival curves according to p53 antibody status for the KRAS mutant-type population (n = 26)Osumi et al. BMC Cancer (2015) 15:Page six ofother hand, lung metastasis and lymph node metastasis were also considerable predictors of PFS. In the multivariate evaluation, peritoneal metastasis was considerable predictors of OS and lung metastasis and lymph.